Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2018; 9(23):4413-4421. doi:10.7150/jca.27342 This issue Cite

Research Paper

Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines

Karolina Sterzyńska1*✉, Andrzej Klejewski2,3*, Karolina Wojtowicz1, Monika Świerczewska1, Michał Nowicki1, Jacek Brązert3, Radosław Januchowski1

1. Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland
2. Department of Nursing, Poznan University of Medical Sciences, Poznań, Poland
3. Department of Obstetrics and Women's Diseases, Poznan University of Medical Sciences, Poznań, Poland
*These authors have contributed equally

✉ Corresponding author: Karolina Sterzyńska, mailing address: Department of Histology and Embryology, Poznan University of Medical Sciences, Święcickiego 6 St., post code 61-781, Poznań, Poland; email address: k.olejniczakedu. More

Citation:
Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Nowicki M, Brązert J, Januchowski R. Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines. J Cancer 2018; 9(23):4413-4421. doi:10.7150/jca.27342. https://www.jcancer.org/v09p4413.htm
Other styles

File import instruction

Abstract

Background: Low effectiveness of chemotherapy in ovarian cancer results from development of drug resistance during treatment. Topotecan (TOP) is a chemotherapeutic drug used in second-line chemotherapy of this cancer. Unfortunately, during treatment cancer can develop diverse cellular and tissue specific mechanisms of resistance to cytotoxic drugs.

Methods: We analyzed development of TOP resistance in ovarian cancer cell lines (A2780 and W1). On the base of our previous results where a set of “new genes” with different functions that can be related to TOP-resistance was described hereby we performed detailed analysis of MYOT expression. MYOT mRNA level (real time PCR analysis), protein expression in cell lysates and cell culture medium (western blot analysis) and protein expression in cancer cells (immunofluorescence analysis) were determined in this study.

Results: We observed increased expression of MYOT in TOP resistant cell lines at both mRNA and protein level. MYOT, together with extracellular matrix molecules like COL1A2 and COL15A1 were also secreted to corresponding cell culture media.

Conclusion: Our results suggest that upregulation of MYOT can be related to TOP resistance in ovarian cancer cell lines.

Keywords: myotilin, ovarian cancer, topotecan resistance

Citation styles

APA
Sterzyńska, K., Klejewski, A., Wojtowicz, K., Świerczewska, M., Nowicki, M., Brązert, J., Januchowski, R. (2018). Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines. Journal of Cancer, 9(23), 4413-4421. https://doi.org/10.7150/jca.27342.

ACS
Sterzyńska, K.; Klejewski, A.; Wojtowicz, K.; Świerczewska, M.; Nowicki, M.; Brązert, J.; Januchowski, R. Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines. J. Cancer 2018, 9 (23), 4413-4421. DOI: 10.7150/jca.27342.

NLM
Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Nowicki M, Brązert J, Januchowski R. Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines. J Cancer 2018; 9(23):4413-4421. doi:10.7150/jca.27342. https://www.jcancer.org/v09p4413.htm

CSE
Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Nowicki M, Brązert J, Januchowski R. 2018. Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines. J Cancer. 9(23):4413-4421.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use